Journal
DRUG DISCOVERY TODAY
Volume 18, Issue 9-10, Pages 447-455Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2012.11.013
Keywords
-
Categories
Funding
- British Heart Foundation
- MRC [U117574559]
- MRC [MC_U117574559] Funding Source: UKRI
- British Heart Foundation [PG/10/52/28448] Funding Source: researchfish
- Medical Research Council [MC_U117574559] Funding Source: researchfish
Ask authors/readers for more resources
The blockade of tumour vascularisation and angiogenesis continues to be a focus for drug development in oncology and other pathologies. Historically, targeting vascular endothelial growth factor (VEGF) activity and its association with VEGF receptors (VEGFRs) has represented the most promising line of attack. More recently, the recognition that VEGFR co-receptors, neuropilin-1 and -2 (NRP1 and NRP2), are also engaged by specific VEGF isoforms in tandem with the VEGFRs has expanded the landscape for the development of modulators of VEGF-dependent signalling. Here, we review the recent structural characterisation of VEGF interactions with NRP subdomains and the impact this has had on drug development activity in this area.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available